IOCBTech is a technology transfer office and subsidiary company of IOCB (the Institute of Organic Chemistry and Biochemistry CAS). The company matches results of basic research done at the IOCB with needs of commercial partners to ultimately bring new ideas in medicinal chemistry, material sciences, and other fields of chemistry to human use.
About IOCB Tech
The IOCB Tech team supports management and decision-making processes in Target Research Groups of IOCB e.g. by due diligence analyses, market potential studies, and project feasibility evaluation. Moreover, the company is responsible for networking and industry partner search or negotiations of contracts and agreements in the field of intellectual property.
An integral part of IOCB Tech’s duties is the organization and development of spin-off companies on IOCB’s technology platform.
MediAim – new therapeutic and drug development strategies
viral RNA isolation kits developed at IOCB and RCPTM
IOCB enters partnership with Neuron Endowment Fund
IOCB Tech donates 7 million CZK to fight coronavirus
SHINE and IOCB Prague deliver Lu-177 dose to GE Healthcare, advance therapeutic isotope
UCT and IOCB Prague establish special research chair
Prague-Weizmann Summer School on Drug Discovery 2019
SHINE and IOCB Prague Enter Lu-177 Process License Agreement
Diamonds of Czech Business – Diamanty českého byznysu
Winter school in DRUG DISCOVERY – Prague-Weizmann Winter School
IOCB Tech at BioVaria 2018
Successful Basel Life Science Week
New granted US patent
Awarded US patent
IOCB projects selected for oral presentation and Spin-off panel at BioVaria 2016